18 February 2019 (Geneva, Switzerland) - The International AIDS Society (IAS) has appointed Roger Tatoud, Ph.D., former Senior Director IAVI – Human Immunology Laboratory Global Operations, to the newly created position of IAS Deputy Director of Programmes and Advocacy (Vaccines).
In his new role, Dr Tatoud will lead the efforts of the IAS and the Global HIV Vaccine Enterprise to speed HIV vaccine development through implementation of the IAS Global HIV Vaccine Enterprise Strategic Plan. The plan outlines a five-year strategy to propel the HIV vaccine pipeline, clarify the road map for future access to a vaccine and expand and diversify the global community of partners working to accelerate HIV vaccine research and development.
“Roger is exceptionally well qualified to guide the efforts of the IAS and our stakeholders at this critically important time for HIV vaccines,” IAS President Anton Pozniak said. “Roger brings more than 20 years of experience in research and public health management, a thorough understanding of the opportunities and obstacles in HIV vaccine research and development and a deep commitment to advancing the development of a vaccine that can help end this epidemic.”
The appointment of Dr Tatoud marks an important milestone in advancing the work of the Global HIV Vaccine Enterprise under the leadership of the IAS. Established more than a decade ago, the Enterprise serves as a neutral convener in the field, promoting coordination, collaboration, knowledge sharing and resource mobilization to accelerate HIV vaccine development. As part of the IAS, the Enterprise is beginning a new era of activity to accelerate the search for an HIV vaccine in the context of emerging opportunities and challenges.
“With several large-scale efficacy trials underway and studies of new approaches flourishing, the HIV vaccine research paradigm is more promising than ever,” Chair of the Vaccine Enterprise Advisory Group Linda-Gail Bekker said. “At the same time, the challenges of sustaining funding and commitment for vaccine research, developing effective trial approaches in a changing prevention environment, navigating regulatory pathways and ensuring access to a future vaccine have never been clearer. We are delighted to have Roger lead the IAS forward in this mission.”
Dr Tatoud said, “I look forward to being part of engaging and strengthening a global movement of stakeholders whose collaborative action can bring us closer to our ultimate goal: a safe and effective vaccine against HIV.”
About the International AIDS Society: The mission of the International AIDS Society (IAS) is to lead collective action on every front of the global HIV response through its membership base, scientific authority and convening power. Founded in 1988, the IAS is the world’s largest association of HIV professionals, with members from more than 160 countries working on all fronts of the global response to HIV. Together, we advocate and drive urgent action to reduce the global impact of HIV. The IAS is also the steward of the world’s two most prestigious HIV conferences: the International AIDS Conference and the IAS Conference on HIV Science. For more information, visit www.iasociety.org.